newsfilter
← Latest News
ClinicalTrials.gov·

Effects of PF-07901801,Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma - NCT05626322

Phase 1b: Dose limiting toxicity (DLT) rate, Phase 2: Objective Response (OR), Phase 1b and Phase 2: Frequency of adverse events (AE), (and 13 more...)